Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 4/20 | 0.53 |
| ▸ | CDK9 | P50750 | 4/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.53 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.53 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.53 |
| ▸ | CDK1 | P06493 | 3/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.53 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.53 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 8/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | JAK2 | O60674 | 2/20 | 0.50 |
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22097771 | 0.89 | CDK19 (0.56) | CDK2CDK9CCNT1CCNB2CCNE2 | |
| SCHEMBL22115067 | 0.88 | JAK1 (0.53) | CDK2CDK9CCNT1CDK1CCNB1 | |
| SCHEMBL22114658 | 0.87 | CCNE2 (0.53) | CDK2CDK9CCNT1CCNB2CCNE2 | |
| SCHEMBL24853389 | 0.87 | IGF1R (0.52) | CDK2CDK9CCNT1CCNB2CCNE2 | |
| SCHEMBL24852784 | 0.86 | MAP3K7 (0.55) | CDK9MAPK1JAK2FLT4MAP3K7 | |
| SCHEMBL24852749 | 0.85 | FLT4 (0.53) | CDK2CDK9CDK1KDRJAK2 | |
| SCHEMBL28608016 | 0.85 | MAPK1 (0.51) | CDK2CDK9CCNT1CCNB2CCNE2 | |
| SCHEMBL22544660 | 0.84 | CDK19 (0.57) | CDK2CDK9CCNT1CCNB2CCNE2 | |
| SCHEMBL29754198 | 0.84 | CDK19 (0.57) | CDK2CDK9CCNT1CCNB2CCNE2 | |
| SCHEMBL24853413 | 0.84 | JAK2 (0.52) | CDK2CDK9JAK2CDK7MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030870-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12030870-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230002362-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| WO-2020118683-A1 | BENZAMIDES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020119819-A1 | BENZAMIDES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030870-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | JAK2, JAK1, JAK3 | CDK2 49/4885CDK9 46/4885CCNT1 1641/4885 |
| US-20230002362-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | CDK2 115/4885CDK9 81/4885CCNT1 2373/4885 |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK2, JAK1, JAK3 | CDK2 49/4885CDK9 46/4885CCNT1 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.